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tion of detected pathogens. For inﬂuenza A, we derive similar relative outbreak clustering in phylogenetic trees
from PathChip-derived compared to classical Sanger-derived sequences. For a positive polio detection, recent in-
fection could be excluded based on vaccine strain similarity.
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Using a random-tag PCR coupled to a high-density Affymetrix hy-
bridization array, the PathChip, developed at the Genome Institute of
Singapore, can detect tens of thousands of virus strains simultaneously
(Wong et al., 2007). The sensitivity and speciﬁcity of the PathChip
were comparable to other molecular diagnostic methods establishing
its capability for use in routine diagnostic laboratories (Simões et al.,
2013). We posited that the genomic data generated from use of this
PathChip on respiratory specimens could be a useful adjunct in epide-
miologic ﬁeld studies and vaccine trials. Due to the nature of the
PathChip design covering more than 25,000 viral genomes, the probe
density for a single pathogen cannot be enough to derive exact se-
quences in the case of fast evolving or less frequently sampled patho-
gens, but instead, the closest hit of a sample to any sequence included
on the chip can be calculated computationally. It is therefore important5-6478-9047.
rer-Stroh).
. This is an open access article underfor proper interpretation to gauge the extent of differences of sequences
derived from classical Sanger sequencing to the best PathChip hits for
the respective same samples. A close match would suggest that poten-
tially the pathogen chip could be used both for detection of viruses in
samples and simultaneously provide data that could point to genetic re-
latedness of samples, paving theway for rapid molecular epidemiologic
investigations.
2. Materials and methods
2.1. Philippine study population and respiratory sample collection
The samples for this study were obtained in Bohol, Philippines, be-
tween 2000 and 2004, from 12,194 participants aged 6 weeks to
23months, with lower respiratory tract infections (LRTI), in a pneumo-
coccal vaccine trial, as detailed before (Lucero et al., 2009). In parallel,
older children from the 6 study areas, aged 24–59 months, not in the
trial, with LRTI were enrolled in a separate epidemiologic study. In-
formed consent was obtained from parents or guardians of all childrenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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for each child to collect respiratory tract specimens. The institutional
boards (IRBs) at the RITM in Manila, Philippines; KTL Finland; and
COMIRB, Aurora, USA, approved the study.
In total, 2066 nasopharyngeal aspirate samples were obtained from
these subjects. Batches of specimens were transported to Denver, CO,
USA, on dry ice, where they were stored at −86 °C. From these, 290
samples were selected for a validation study of the PathGEN PathChip
platform in comparisonwith other pathogen diagnostics systems to de-
termine the robustness of this platform. The wet lab processing
methods used are described in the previous work (Simões et al.,
2013). This current work adds the epidemiological detailed perspective
for 14 inﬂuenza A H3N2–positive samples and 1 poliovirus-positive
sample for which Sanger-derived sequences could be obtained (see
below).
2.2. Inﬂuenza samples
The nasal wash samples (Lucero et al., 2009) whichwere previously
identiﬁed as having inﬂuenza (Simões et al., 2013) were assayed using
PCR to subtype and sequence the sample. RNA was extracted from the
nasal washes using TRIzol LS (Life Technologies, Grand Island, NY,
USA) according to the manufacturer's suggested protocol. cDNA for in-
ﬂuenza was produced using SuperScript III ﬁrst strand synthesis system
for RT-PCR (Life Technologies) using the primer Uni12W for inﬂuenza A
samples (WHO, 2009). PCR for the hemagglutinin was completed using
a nested PCR approach. World Health Organization primers and proto-
cols were used to obtain the genes and then sequence them (WHO,
2009). The bands were visualized on a 1% agarose gel then sequenced
using the Sanger method.
2.3. Poliovirus sample
A nasal wash sample (Lucero et al., 2009) which was identiﬁed as
possibly being positive for poliovirus (Simões et al., 2013) underwent
PCR for the VP1 region. The VP1 region was selected for PCR and se-
quencing for its speciﬁc deﬁning properties of poliovirus (Oberste et al.,
1999). cDNA was produced using the SuperScript III ﬁrst-strand synthe-
sis system for RT-PCR kit (Life Technologies) using random hexamers.
PCR was carried out using the previously described Y7R and Q8 primers
(Kilpatrick et al., 2011) using Thermo-Start polymerase (Thermo Scien-
tiﬁc, Pittsburgh, PA, USA) according to themanufacturer's recommenda-
tions. The cycling conditions were as follows: 95 °C for 15 minutes,
35 cycles of 95 °C for 30 seconds, 52 °C for 30 seconds, and 72 °C for
1 minute, followed by 72 °C for 7 minutes. The band was visualized on
a 1% agarose gel then sequenced using the Sanger method.
2.4. Indonesian study population and respiratory sample collection
The Indonesian samples were obtained from a population-based
study in rural West Java, Bandung, Indonesia, to estimate the burden
of inﬂuenza in 2008. We conducted daily surveillance in the ﬁrst level
health center (Puskesmas) in Soreang and Cileunyi subdistricts, Ban-
dung West Java Province, Indonesia. A total of 197 children and adults
with Inﬂuenza-like illness (ILI) were recruited (nasal wash/swab speci-
mens), and PCR of nasal specimens revealed that 69 had inﬂuenzaA and
1 had inﬂuenza B. The PCR protocol is identical to the previous study, and
IRB approval is included as listed above with additional IRB approval at RS
Hasan Sadikin hospital, Indonesia. Four samples thatwere conﬁrmed to be
H3N2 inﬂuenzaA in 2008were also testedwith the PathChip, and the clos-
est matching sequence was determined (see below).
2.5. PathChip and PathChip-derived sequences
The PathChip and its usage protocol have been extensively described
before (Simões et al., 2013; Wong et al., 2007). Brieﬂy, the basicassumption underlying the PathChip protocol assumes that the re-
searcher/physician does not know what pathogen is contained within
the sample. As such, sample preparation includes a single-tube PCR re-
action, using a semirandom approach. PCR bias is avoided during the
assay design process, using the LOMA algorithmwepublished previous-
ly (Lee et al., 2008). The next step is hybridization to an array in
Affymetrix custom GeneChip cartridge format consisting of probes uni-
formly spaced out across 25,000 full viral genome sequences from 59
genera organized in 154 clinically relevant groups. The PDA algorithm
was used to predict the pathogen recognition signatures for each ge-
nome on the chip (Wong et al., 2007). For inﬂuenza A, B, and C and po-
liovirus, the chip provides genome coverage for 13467, 2673, 204, and
56 strains/isolates, respectively. Relevant for this study, eachH-orN- in-
ﬂuenza subtype is detected by separate pathogen recognition signa-
tures comprising an average of 100 probes. The Affymetrix image ﬁle
is automatically analyzed by the accompanying software (Wong et al.,
2007) which presents as output assay quality control metrics and the
identiﬁed pathogen recognition signatures, including the NCBI GenInfo
number of the closest matching pathogen genome in the database
(Simões et al., 2013). In this study, we refer to a PathChip-derived se-
quence as the sequence of the closest known genome hit detected by
PathChip.
2.6. Multiple alignments and phylogenetic trees
For each nucleotide sequence set derived from the 2 methods, mul-
tiple alignments were created with MAFFT using L-INS-I parameters
(Katoh and Standley, 2014), and phylogenetic trees were inferred by
using the maximum likelihood method based on the Tamura–Nei
model (Tamura and Nei, 1993) with a discrete gamma distribution to
consider evolutionary rate differences among sites (5 categories, includ-
ing invariable) in MEGA6 (Tamura et al., 2013). For Fig. 1D, inﬂuenza A
H3N2 vaccine strains were downloaded from the NCBI Inﬂuenza Virus
resource (Bao et al., 2008) and multiple alignments and phylogenetic
trees derived as described above.
2.7. Tree similarity
To test signiﬁcance of phylogenetic tree similarity, we compare the
measure of exactly agreeing triplets (Estabrook et al., 1985) as distance
between the Sanger and PathChip hit trees with the same distance for
randomly permutated trees (randomization tests over 100 trees as im-
plemented in TOPD (Puigbò et al., 2007)).
3. Results and discussion
First, we evaluated a hit for a poliovirus identiﬁed in 1 of the speci-
mens from the previous study of samples from the Philippines
(Simões et al., 2013). Compared to classical Sanger sequencing, the
PathChip-derived best hit sequence was found to be 96% identical
over a sequence length of 1000 nucleotides (VP1 region). While this is
clearly limited by the sampling density of polioviruses available in the
databases, both the Sanger- and PathChip-derived sequences were
more closely related to the Sabin type 1 vaccine reference strain
(98.5% and 97.5%, respectively) than to recent Philippine outbreak
strains (95.6% and 95.8%) suggesting recent immunization for this pa-
tient with the live attenuated vaccine and not infection with a wild-
type strain circulating at the time (Shimizu et al., 2004).
Next, we have previously shown that the PathChip can readily dis-
tinguish different inﬂuenza subtypes with hits for inﬂuenza A H3N2
and H1N1 as well as inﬂuenza B and the rare or less well studied inﬂu-
enza C. In this study, we attempt the more difﬁcult task of within sub-
type clustering. We had to focus on H3N2 since the numbers of
detection of the other subtypeswere too few to be interpreted epidemi-
ologically (Simões et al., 2013).
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Fig. 1. PathChip hit trees match Sanger sequence trees. H3 hemagglutinin phylogenetic trees of (A) PathChip hits and (B) Sanger sequences both derived from the same samples. Colored
bars connect corresponding samples. (C) Tree distance measure for the 2 trees above compared to average distance of 100 randomly permutated trees. (D) Phylogenetic tree of PathChip
hit sequences with H3N2 vaccine strains.
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using classical Sanger protocols, and sequences were also computation-
ally derived from the PathChip best hits result for the same samples. On
average, the PathChip-derived sequences were 98.9% identical to their
Sanger controls (97.6–99.7%) over sequence lengths from 1200 to
1700 nucleotides, which is substantially better than for the poliovirus
example due to the intense global inﬂuenza surveillance efforts. Never-
theless, BLAST (Altschul et al., 1997) hits of the Sanger-derived se-
quences against GenBank (Benson et al., 2011) indicate that they are
most similar to clusters inMalaysia, HongKong, or Australia, respective-
ly, and not the Philippines showing that inﬂuenza A H3N2 strains in the
Philippines during the sample period were not well represented in the
database. This also means that the immediate virus strains from the ob-
tained samples are also not included in the used version of the chip,
therefore representing a realistic scenario of how the PathChip hit pro-
ﬁle resultwould look like for slightly distinct or drifted strains, expected
during typical inﬂuenza A evolution (Rambaut et al., 2008). Interesting-
ly, the inﬂuenza samples analyzed with PathChip could nevertheless be
distinguished among each other by their relative hit proﬁle to different
groups of strains reminiscent of outbreak clustering seen with normal
sequences.
To see if this relative clustering matches that of Sanger-derived se-
quences, we created phylogenetic trees for each nucleotide sequence
set derived from the 2 methods. Fig. 1A and B shows that the corre-
sponding phylogenetic trees for both methods are, as expected, notperfect but indeed similar. Nine of the 14 samples are exactly matched
to the same cluster in the trees, and another 3 match at least to the
neighboring cluster asserting reasonable agreement in 86% of the sam-
ples. To test signiﬁcance of this tree similarity, we compare the Sanger
and PathChip hit trees with randomly permutated trees and ﬁnd that
the agreement of PathChip hit and direct sequence trees is at least 2
SDs better than the random average (Fig. 1C). Agreement of triplets
(measure used here, see Methods) is important for interpretation of
samples with regard to outbreak clustering indicating that PathChip re-
sults could be used for this.
Another validation is if the identiﬁed best PathChip hit sequences
would ﬁt into the known evolutionary pattern and history of inﬂuenza
as reﬂected by WHO-recommended vaccine strains. Indeed, all sample
sequences are found between or with vaccine strains of their expected
time period 2002–2004 (Fig. 1D, pink dots). To show that the approach
is robust and able to distinguish samples from different seasons, we ap-
plied the same procedure for H3N2 inﬂuenza A samples from another
surveillance study in Indonesia in 2008 where PCR-positive hits were
also concurrently tested with the PathChip. Also in this case, the
PathChip-derived sequences are ﬁtting to their expected time period
in between the respective vaccine reference strains (Fig. 1D, yellow
dots).
We are aware that the necessary array coverage to obtain reasonable
matches through closest genome hit matches strongly depends on the
respective pathogen's representation in the database used to design
206 S. Maurer-Stroh et al. / Diagnostic Microbiology and Infectious Disease 84 (2016) 203–206the array/chip. We chose here inﬂuenza as example because there is
good database coverage due to the global surveillance efforts, and it is
an important commonly encountered pathogen where epidemiological
interpretation can help in public health decisions. Given that there re-
mains a discrepancy of the closest genome match with the Sanger-
derived sequences, secondary conﬁrmation of the sequence details
would be recommended by a complementary method, while our and
similar chip protocols could be useful for large-scale screens to identify
which samples and sequences are of greater interest to be studied in
more detail.
4. Conclusions
In summary, we show that PathChip-derived best hit sequences can
be used for epidemiological interpretation through relative phylogenet-
ic tree clustering even for fast evolving pathogens such as inﬂuenza.
Speciﬁcally, one can identify outbreak clusters including vicinity to pre-
vailing vaccine strains. We note that these ﬁndings on usability of rela-
tive hit clustering may not be unique to the tested PathChip platform
but could be equally useful for other PCR-coupled hybridization array
systems for pathogen detection, although this requires further studies.
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